Peer-reviewed veterinary case report
Safety of giving capromorelin daily to cats for up to 91 days
By Wofford, J A et al.·Published in Journal of veterinary pharmacology and therapeutics·2018·Aratana Therapeutics, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of the safety of daily administration of capromorelin in cats.
- Species:
- cat
Plain-English summary
A group of cats was given a medication called capromorelin daily to see if it was safe for stimulating appetite. Some cats experienced side effects like vomiting, drooling, lethargy, head shaking, and lip smacking, but these were not severe. Overall, the medication did not cause any significant changes in blood tests compared to the cats that received a placebo. The study suggests that while some cats may have mild reactions, capromorelin can be safely used for appetite stimulation in cats.
People also search for: cat appetite stimulant side effects · capromorelin for cats · why is my cat vomiting after medication
Abstract
Capromorelin is a ghrelin receptor agonist that is FDA approved for appetite stimulation in dogs. The objective of this study was to evaluate the safety of daily oral administration of capromorelin to cats over a range of doses and for an extended period. Two randomized, controlled studies were conducted: in Study 1, cats (n = 6 per group) received placebo or capromorelin at a dose of 9, 15, 30 or 60 mg/kg once daily for 14 days; and in Study 2, cats received capromorelin at 6 mg/kg (n = 8) or placebo (n = 4) once daily for 91 days. Cats were evaluated using clinical observations and clinical pathology test results for both studies, with the addition of postmortem examination in Study 1 and measurements of growth hormone and insulin-like growth factor 1 in Study 2. Abnormal clinical observations were limited to emesis, hypersalivation, lethargy/depression, head shaking and lip smacking, which occurred more frequently in the capromorelin-treated groups than in the placebo group. There were no clinically relevant differences in clinical pathology test results between the capromorelin and placebo groups in either study.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29057482/